European Pharmaceutical Review

MAY 7, 2024

A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Injectable drugs are adopted widely as treatments for chronic infections such as HIV/AIDS and tuberculosis (TB).

Marketing 94

Marketing Food and Drug Administration Government Food 94

European Pharmaceutical Review

FEBRUARY 5, 2024

Incentivising small molecule drug innovation According to the Biotechnology Innovation Organization (BIO), the bipartisan Ensuring Pathways to Innovative Cures ( EPIC Act ) passed last week in the US, is a “critical” step for incentivising small molecule drug innovation.

Food and Drug Administration 97

Food and Drug Administration Medicine Food Pharmaceutical 97

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. Viatris is seeking approval from the US Food and Drug Administration (FDA) to market Januvia and Janumet’s generic versions in the country.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

Pharmaceutical Technology

APRIL 24, 2023

Brukinsa was approved by the US Food and Drug Administration (FDA) in CLL in January 2023. billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in 2029. According to GlobalData’s Pharma Intelligence Centre, a sales consensus forecasts Brukinsa to have global sales of $3.98

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

Pharmaceutical Technology

APRIL 4, 2023

The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. billion in 2029.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. However, current orthopedic medical device trends all point towards the increasing use of such systems.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Medico Reach

OCTOBER 17, 2022

billion by 2029. Quite recently, the Food and Drug Administration (FDA) marked a historical moment when it approved Patient Specific Talus Spacer 3D-printed implants in 2021. However, current orthopedic medical device trends all point towards the increasing use of such systems.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52